Incyte Advances Blood Cancer Drugs Ahead of December Data Release

Incyte

WILMINGTON, DE — Incyte (Nasdaq: INCY) will present new clinical findings for its experimental blood cancer and bleeding disorder treatments at the American Society of Hematology’s annual meeting Dec. 12-15 in New Orleans, providing further evidence of its efforts to expand beyond established therapies through drugs targeting specific disease mechanisms.

The Wilmington-based biopharmaceutical company plans more than 30 research presentations, led by updated results for INCA033989, an investigational antibody targeting mutant calreticulin, or mutCALR, in patients with myelofibrosis and essential thrombocythemia.

The presentations will include early clinical findings in previously untreated myelofibrosis patients, updated results in patients who have received prior treatment, and research supporting the development of additional mutation-targeted compounds.

The data are particularly relevant to Incyte’s strategy of developing therapies directed at genetic abnormalities associated with myeloproliferative neoplasms, a group of disorders involving abnormal blood cell production.

In a Phase 1 study involving myelofibrosis patients who had not previously received JAK inhibitors, INCA033989 was reported to be well tolerated and associated with improvements in spleen enlargement, symptoms and anemia.

Those findings will be presented Dec. 12, while separate Phase 1 results examining molecular responses and restoration of normal blood cell production in essential thrombocythemia are scheduled for Dec. 14.

Incyte will also present updated findings for INCA033989 used alone or with ruxolitinib in myelofibrosis patients whose disease relapsed, resisted treatment or responded inadequately to previous therapy.

READ:  Phreesia Executive Recognized for $5 Billion Payments Role

The company is advancing the antibody into later-stage development through EXCALIBUR-ET2, a randomized Phase 3 trial comparing INCA033989 with available treatments in patients with high-risk essential thrombocythemia who have responded inadequately to cytoreductive therapy.

The program represents an effort to move beyond conventional treatment approaches by targeting the mutant protein associated with disease development.

Incyte is also developing next-generation compounds directed at mutCALR and JAK2V617F, another mutation associated with myeloproliferative neoplasms.

Preclinical findings for INCB203954, a selective JAK2V617F inhibitor, will be presented Dec. 13. Additional research involving INCA041798, a next-generation mutCALR-targeting antibody designed for extended activity across clinically relevant mutation variants, is scheduled for Dec. 14.

The presentations will also feature long-term findings for latarcibart, an investigational antibody intended to prevent bleeding in patients with von Willebrand disease, an inherited bleeding disorder.

Latarcibart targets Protein S to promote platelet attachment and fibrin formation, mechanisms involved in controlling bleeding.

Results from a Phase 1/2 open-label extension study involving adolescents and adults will examine the treatment’s longer-term efficacy and safety.

The therapy is being developed as a once-monthly, self-administered subcutaneous injection and has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration.

Incyte acquired latarcibart in July 2026 through its acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics.

READ:  Qnity Raises 2026 Outlook as Semiconductor Sales Jump 22%

The drug has since advanced into the Phase 3 VIVID-6 study, which is evaluating its safety and efficacy in preventing bleeding across all types of von Willebrand disease, including patients with substantial disease burdens.

“We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD),” said Pablo J. Cagnoni, Incyte’s president and global head of research and development.

Beyond its experimental programs, Incyte will present additional findings involving established hematology and oncology treatments.

The company’s lymphoma research includes analyses from the Phase 3 frontMIND trial evaluating tafasitamab, marketed as Monjuvi, in combination with lenalidomide and the R-CHOP chemotherapy regimen for previously untreated diffuse large B-cell lymphoma.

The presentations will examine clinical outcomes among patients with partial metabolic responses, differences by age and molecular responses associated with treatment.

Additional research involving tafasitamab will address relapsed or refractory follicular lymphoma, including results from the Phase 3 inMIND study and comparisons with other treatment combinations.

Monjuvi is already approved in the United States for certain patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma.

Incyte will also present long-term efficacy and safety findings for axatilimab, marketed as Niktimvo, in chronic graft-versus-host disease, a complication that can occur after stem cell transplantation.

READ:  West Pharmaceutical to Address Investors at London Conference

The research includes subgroup analyses from the AGAVE-201 trial and studies examining biological changes associated with treatment response.

Niktimvo is approved in the United States for chronic graft-versus-host disease following failure of at least two previous systemic therapies in eligible adult and pediatric patients.

Additional clinical trials are evaluating axatilimab in combination with ruxolitinib and corticosteroids for earlier treatment of the condition.

Research involving ruxolitinib, marketed as Jakafi, will examine treatment patterns in 1,555 U.S. patients with myelofibrosis, genetic mutation dynamics and proposed classifications for progressive polycythemia vera.

The broader research program combines clinical development of experimental therapies with additional studies of marketed drugs, supporting Incyte’s efforts to extend its hematology portfolio across blood cancers and related disorders.

Incyte will discuss the findings during an investor event and webcast Dec. 12 from 8:30 to 10 p.m. Eastern time. Registration is available at https://incyte-investor-event-ash-2026.open-exchange.net/registration.

The webcast will also be accessible through the investor section of Incyte’s website, with a replay available for 30 days.

Additional information about the American Society of Hematology’s annual meeting is available at https://www.hematology.org/meetings/annual-meeting.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.